Eli Lilly and Company $LLY is Catalio Capital Management LP’s 4th Largest Position

Catalio Capital Management LP reduced its position in Eli Lilly and Company (NYSE:LLY) by 54.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 25,923 shares of the company’s stock after selling 31,453 shares during the quarter. Eli Lilly and Company makes up about 5.2% of Catalio Capital Management LP’s holdings, making the stock its 4th largest position. Catalio Capital Management LP’s holdings in Eli Lilly and Company were worth $27,859,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after purchasing an additional 1,006,885 shares in the last quarter. State Street Corp grew its position in shares of Eli Lilly and Company by 1.8% in the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after purchasing an additional 635,358 shares in the last quarter. Capital Research Global Investors grew its position in shares of Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares in the last quarter. Morgan Stanley grew its position in shares of Eli Lilly and Company by 2.7% in the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after purchasing an additional 407,166 shares in the last quarter. Finally, Capital World Investors grew its position in shares of Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after purchasing an additional 61,851 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,111.43 on Thursday. The firm has a market capitalization of $1.05 trillion, a price-to-earnings ratio of 39.48, a P/E/G ratio of 1.23 and a beta of 0.53. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,182.73. The stock has a fifty day moving average of $1,009.79 and a 200 day moving average of $1,016.67. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were paid a dividend of $1.73 per share. The ex-dividend date of this dividend was Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly expanded its neuroscience and pain pipeline by acquiring 4E Therapeutics, a move that could add a non-opioid chronic pain opportunity and diversify growth beyond obesity drugs. Lilly buys non-opioid pain drugmaker 4E
• Positive Sentiment: The company also continues to advance multiple clinical programs, including new studies in Alzheimer’s, neurology, psoriasis, and pain, reinforcing expectations that Lilly can keep building future revenue streams. Lilly Expands Donanemab Ambitions With New Lewy Body Dementia Trial
• Positive Sentiment: Separately, commentary from Jim Cramer urging investors to stay in the stock may have helped sentiment around Lilly’s long-term growth story. Jim Cramer on Eli Lilly: “I Want You to Stay in the Stock”
• Neutral Sentiment: Johnson & Johnson’s decision to stay out of obesity drugs is a reminder that Lilly’s blockbuster GLP-1 franchise remains a major competitive advantage, but it does not directly change Lilly’s near-term fundamentals. J&J Skips GLP-1 Race, Targets No. 1 Cancer Spot By 2030
• Negative Sentiment: The biggest drag is Lilly’s decision to cut its planned Germany investment in half, citing European drug-pricing reforms that could hurt future R&D and manufacturing economics. That raises concern about international margins and capital allocation. Eli Lilly (LLY) Halves $2.7 Billion Germany Investment Over Europe Drug Pricing
• Negative Sentiment: Broader reporting on big pharma pressure tactics in Europe keeps regulatory and pricing risk in focus for Lilly and other drugmakers, which may weigh on investor sentiment if pricing fights escalate. Big pharma taps UK playbook to pressure Europe on drug prices

Analyst Ratings Changes

Several equities analysts have recently weighed in on LLY shares. HSBC cut Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their price target for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Barclays lifted their price target on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Weiss Ratings cut Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, May 19th. Finally, Guggenheim reiterated a “buy” rating and issued a $1,183.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average target price of $1,227.74.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.